BioAtlantis will bring Digestica to the market in 2023 to help humans prime the body to deal with methabolic issues

BioAtlantis is developing nutraceutical compositions targeting immunological, metabolic and stress-related conditions in humans. This technology is based on the use of natural compounds that modulate biological processes in humans, with efficacy proven in a diverse range of cohorts. Our flagship nutraceutical, Digestica®, is based on a unique composition that works in vivo to address immunological and metabolic abnormalities. The market launch is planned for 2023.